Table A1.
Trials Included in the ACCENT Data Set
| Trial | Accrual Period | Treatment Arm(s) | No. of Patients |
|---|---|---|---|
| NSABP C-01 | 1977-1983 | Control v MOF | 724 |
| NCCTG 784852 | 1978-1984 | Control v FU/LEV | 247 |
| FFCD | 1982-1990 | Control v FU/LV | 239 |
| NSABP C-02 | 1984-1988 | Control v PVI FU | 896 |
| INT 0035 | 1984-1987 | Control v FU/LEV | 926 |
| Siena | 1985-1990 | Control v FU/LV | 256 |
| NCIC | 1987-1992 | Control v FU/LV | 359 |
| NSABP C-03 | 1987-1989 | MOF v FU/LV | 1,042 |
| NCCTG 874651 | 1988-1989 | Control v FU/LV | 408 |
| GIVIO | 1989-1992 | Control v FU/LV | 867 |
| NCCTG 894651 | 1989-1991 | FU/LV ± LEV for 6 or 12 months | 915 |
| NSABP C-04 | 1989-1990 | FU/LEV v FU/LV v FU/LV/LEV | 2,083 |
| INT 0089 | 1990-1992 | FU/LEV v FU/LV (HD or LD) v FU/LV/LEV | 3,561 |
| NSABP C-05 | 1991-1994 | FU/LV v FU/LV + IFN | 2,136 |
| NCCTG 914653 | 1993-1998 | FU/LV + HD or standard LEV | 878 |
| SWOG 9415 | 1994-1999 | Bolus v infusional FU/LEV/LV | 939 |
| QUASAR | 1994-1997 | FU/LV (HD or LD) ± LEV | 3,517 |
| GERCOR | 1996-1999 | Bolus v infusional FU/LV | 905 |
| Total | 20,898 |
Abbreviations: ACCENT, Adjuvant Colon Cancer Endpoints; NSABP, National Surgical Adjuvant Breast and Bowel Project; MOF, semustine, vincristine, and fluorouracil; NCCTG, North Central Cancer Treatment Group; FU, fluorouracil; LEV, levamisole; FFCD, Fédération Francophone de Cancérologie Digestive; LV, leucovorin; PVI, protracted venous infusion; INT, Intergroup; NCIC, National Cancer Institute of Canada; GIVIO, Gruppo Interdisciplinare Valutazione Interventi Oncologia; HD, high dose; LD, low dose; IFN, interferon alfa-2a; SWOG, Southwest Oncology Group; QUASAR, Quick and Simple and Reliable; GERCOR, Groupe Cooperateur Multidisciplinaire en Oncologie.